Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis

Kaijun Zhang,1 Xin Zou,1 Zhiyi Ma,1 Xiaohong Liu,1 Chencheng Qiu,2 Lingyan Xie,1 Zhaosheng Lin,1 Saiyu Li,1 and Yongming Wu1

1Department of Pulmonary and Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, China
2Department of Respiratory Medicine, Shanghang County Hospital, Longyan 364200, China

Correspondence should be addressed to Xin Zou; cynthia3515@163.com and Zhiyi Ma; fjlymzy@163.com

Received 16 November 2021; Accepted 11 January 2022; Published 8 March 2022

Academic Editor: Pierachille Santus

This study aims to investigate the risk factors associated with impaired pulmonary diffusing capacity among patients with noncystic fibrosis bronchiectasis (NCFB) and compare the predictive value of several scoring systems for the impairment in these patients. Between July 2019 and June 2021, patients who were admitted to the hospital and diagnosed with NCFB were included in this study. Clinical data were collected and analyzed retrospectively. A total of 175 NCFB patients were included in the analysis. Multivariate logistic regression analysis revealed that impaired pulmonary diffusing capacity diagnosed by carbon monoxide diffusing capacity (DLCO) <80% prediction was associated with age, Reiff score, body mass index (BMI), comorbid chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). Disease duration, frequency of exacerbation, hemoglobin level, and COPD were independent risk factors for impaired pulmonary diffusing capacity diagnosed by DLCO/alveolar volume (VA) <80% prediction. Age, Reiff score, and smoking status were independent risk factors for decreased VA diagnosed by VA <80% prediction. The areas under the curve (AUC) for discrimination of DLCO <80% prediction were 0.822 (0.760–0.885) for Bronchiectasis Severity Index (BSI), 0.787 (0.718–0.856) for FACED, 0.795 (0.729–0.863) for E-FACED, and 0.767 (0.694–0.839) for modified Medical Research Council (mMRC) scores; the AUC for discrimination of DLCO/VA <80% prediction was 0.803 (0.727–0.880) for BSI, 0.752 (0.669–0.835) for FACED, 0.757 (0.676–0.839) for E-FACED, and 0.762 (0.679–0.845) for mMRC, respectively. The BSI had the largest AUC, but the differences between those scoring systems had no statistical significance (P = 0.181 for DLCO <80% prediction and P = 0.105 for DLCO/VA <80% prediction). The mMRC score (up to 2 grades) showed a high specificity for discriminating diffusing dysfunction (88.3% for DLCO <80% prediction and 76.1% for DLCO/VA <80% prediction). In NCFB patients, several factors such as age, Reiff score, BMI, exacerbation frequency, disease duration, and comorbid COPD and ILD were associated with impaired pulmonary diffusing capacity, which requires more attention in managing those patients. In addition, several scoring methods, including a simple index of mMRC, showed a comparable and moderate performance for predicting pulmonary diffusing impairment and would facilitate the systematic evaluation of the diffusing capacity of NCFB patients.

1. Introduction

Noncystic fibrosis bronchiectasis (NCFB) is a multidimensional disease with various etiologies and multiple mechanisms, leading to different degrees of severity and prognosis [1]. The incidence of NCFB in the UK was 35.2 per 100,000 person-years among women in 2013 and 26.9 per 100,000 person-years among men [2]. Moreover, increasing trends in incidence and mortality have been observed in the UK [2]. Similarly, in Germany, the incidence of NCFB was estimated to be 21.23 per 100,000 inhabitants in 2013 [3]. Among Asians older than 65 years, the prevalence of bronchiectasis is 2.5- to 3.9-fold higher than that in white and black populations [4]. The prevalence of bronchiectasis in Korea was reported to be 9.1% in adults [5]. Although the prevalence of bronchiectasis among the population over 40
years old in China was estimated at 1.2%, the actual prevalence may be higher because only diagnosed patients were included [6].

As a simple, safe, and noninvasive procedure, pulmonary function examination is widely performed for patients with respiratory diseases. Abnormal pulmonary ventilation function is easily found in patients with bronchiectasis, which is associated with the extent and severity of bronchial damage and coexisting factors, such as smoking status and comorbidities such as asthma or chronic obstructive pulmonary disease (COPD). The forced expiratory volume in 1 s (FEV1) is one of the most popular parameters for assessing the degree of lung function impairment in patients with bronchiectasis. It is incorporated into scoring systems for the evaluation of bronchiectasis severity, such as the Bronchiectasis Severity Index (BSI) [7], FACED [8], and E-FACED scores [9]. Moreover, most studies addressing the role of pulmonary function parameters in NCFB patients with lung function impairment focused on pulmonary ventilation parameters, such as FEV1 decline. Other pulmonary functional parameters, such as the pulmonary diffusing capacity, seem to be independent predictors for the mortality of patients with bronchiectasis [10].

Unfortunately, the risk factors associated with impaired pulmonary diffusing capacity in NCFB patients remain unclear. Therefore, additional research is required to identify individuals at high risk of death and improve the management of NCFB. Moreover, the predictive role of the above scoring systems for impaired pulmonary diffusing capacity among NCFB patients remains largely undefined. Thus, another aim of the study is to investigate the predictive roles of the scoring systems.

2. Materials and Methods

2.1. Ethics. The study protocol was approved by the Ethics Review Committee of the First Hospital of Longyan, Fujian Medical University. Written informed consent was obtained from all patients included in the study.

2.2. Subjects. Between July 2019 and June 2021, patients admitted to our center and diagnosed with bronchiectasis using computerized chest tomography (CT) were recruited for further analysis. Patients were excluded if they met the following criteria: (1) cystic fibrosis bronchiectasis, (2) pulmonary tuberculosis, (3) lung cancer, (4) severe immune suppression, such as transplantation and acquired immunodeficiency syndrome (AIDS), (5) new onset of relatively severe pneumonia, and (6) no pulmonary function examination.

2.3. Data Collection and Definition. Data, such as age, height, weight, body mass index (BMI), smoking, medical history, symptoms, hemoglobin, acute exacerbation episode, underlying diseases, pulmonary function examinations, and sputum culture, were collected on admission or during hospitalization. Scoring systems, such as the BSI, FACED, E-FACED, modified Medical Research Council (mMRC), and Reiff scores, were estimated and analyzed.

Impaired diffusing capacity was considered as carbon monoxide diffusing capacity (DLCO) or the coefficient of transfer factor (DLCO/Alveolar volume (VA)) <80% prediction. Ventilation dysfunction was defined as follows: obstructive ventilation dysfunction (FEV1/forced vital capacity (FVC)% <70% with FEV1% <80% prediction and FVC ≥80% prediction; or FEV1/FVC% <70% with FVC <80% prediction but total lung volume (TLC, %) ≥80% prediction; or FEV1%/FVC% ≥70% with FVC <80% prediction but TLC ≥80% prediction), restrictive ventilation dysfunction (FEV1/FVC% ≥70% with TLC <80% prediction), mixed ventilatory dysfunction (FEV1/FVC% <70% with FVC <80% prediction and TLC <80% prediction), nonspecific ventilation dysfunction (FEV1/FVC% ≥70% and TLC >80% prediction, but FEV1 <80% prediction or FVC <80% prediction), air-trapping (residual volume (RV)/TLC % >40%), and overinflation (TLC >120% prediction). The mMRC dyspnea score was evaluated based on the following rules: Grade 0 (I only get breathless with strenuous exercise); Grade 1 (I get short of breath when hurrying on level ground or walking up a slight hill); Grade 2 (I walk slower than people of the same age on level ground because of breathlessness, or I have to stop for breath when walking at my own pace on level ground); Grade 3 (I stop for breath after walking ~100 meters or after a few minutes on level ground); Grade 4 (I am too breathless to leave the house or I am breathless when dressing); and (3) The modified Reiff score was recorded by assessing the radiographic extension (tubular: 1 point, varicose: 2 points; cystic: 3 points) and the lingula lobe as a separate lobe, with a total score ranging from 0 to 18 points. The BSI [7], FACED [8], and E-FACED [9] scores were all calculated as previously reported.

2.4. Statistical Analysis. SPSS 26.0 software was used to perform the statistical analysis. If the normal distribution was observed in the continuous variables, the data were expressed as mean ± standard deviation (SD), and a t-test was used to compare the groups. Otherwise, the data were expressed as the median and interquartile range values, and a rank-sum test was used for comparisons between groups. Categorical variables were presented as counts and percentages, and the chi-square test or Fisher’s exact test was performed for comparisons. Variables with a P value of <0.05 in the univariate analysis were included in the multivariate analysis using stepwise regression models to identify corresponding risk factors. Receiver-operating characteristic (ROC) curves constructed with Stata 15.0 were used to evaluate the predictive value of several measurements or scoring systems for impaired pulmonary diffusing capacity. The sensitivity, specificity, Youden index, area under the curve (AUC), and optimal cutoff values were calculated. A P value less than 0.05 was considered to indicate a significant difference.

3. Results

3.1. Baseline Characteristics. Data on 223 hospitalized patients with NCFB were collected cross-sectionally during the study period. After exclusion, a final cohort of 175 NCFB
patients (age range, 16–88 years) was included. Table 1 shows the characteristics of the included patients. 106 (60.6%) patients were men, and 77 (44%) were smokers or previous smokers. Additionally, 34 (19.4%), 85 (48.6%), and 56 (32.0%) patients were underweight (BMI < 18.5 kg/m²), normal weight (BMI 18.5–24 kg/m²), and overweight (BMI > 24 kg/m²), respectively.

Among the 175 patients, 49 (28.0%) had obstructive ventilation dysfunction, 38 (21.7%) had restrictive ventilation dysfunction, 41 (23.4%) had mixed ventilatory dysfunction, 3 (1.7%) had nonspecific ventilation dysfunction, 133 (76.0%) had air trapping, and only one patient had pulmonary overinflation. In addition, 81 (46.3%) patients had diffusion dysfunction diagnosed by DLCO < 80% prediction, 41 (23.4%) patients had diffusion dysfunction diagnosed by DLCO/VA < 80% prediction, and 90 (51.4%) patients had decreased alveolar volume diagnosed by VA < 80% prediction. Patients with restrictive ventilation dysfunction, mixed ventilatory dysfunction, and air-trapping were significantly likely to have pulmonary diffusion dysfunction diagnosed by DLCO < 80% prediction (Figure 1(a)).

The prevalence of pulmonary diffusion dysfunction diagnosed by DLCO/VA < 80% prediction was significantly higher in patients with mixed ventilatory dysfunction and air-trapping (Figure 1(b)). Similarly, decreased VA diagnosed by VA < 80% prediction was more likely to happen in patients with restrictive ventilation dysfunction and air-trapping, but less likely to happen in patients with obstructive ventilation dysfunction (Figure 1(c)).

3.2. Risk Factors of Impairment in Pulmonary Diffusing Capacity and Decreased Alveolar Volume. Univariate analysis revealed that age, BMI, smoking status, hemoglobin, disease duration, Pseudomonas aeruginosa colonization, exacerbation frequency, recent hospitalization (< 2 years), Reiff score, cystic bronchial dilation, COPD, asthma, ILD, pulmonary artery hypertension (PAH), and cardiovascular disease were significantly different in patients with and without impaired pulmonary diffuse capacity diagnosed by DLCO < 80% prediction. Age, BMI, disease duration, smoking status, hemoglobin, exacerbation and hospitalization frequency (< 2 years), Reiff score, COPD, and PAH were significantly different in patients with and without impaired pulmonary diffused capacity diagnosed by DLCO/VA < 80% prediction. Age, male sex, BMI, disease duration, smoking status, Reiff score, COPD, and PAH were significantly different in patients with and without VA < 80% prediction (Table 1).

Subsequently, multivariate stepwise logistic regression analysis was performed, and the results showed that older age, lower BMI, higher Reiff score, COPD, and ILD were independent risk factors for impaired pulmonary diffusing capacity diagnosed by DLCO < 80% prediction among patients with NCFB (Table 2). Disease duration, frequency of exacerbation, hemoglobin, and COPD were independent risk factors for impaired pulmonary diffusing capacity diagnosed by DLCO/VA < 80% prediction (Table 2). Age, Reiff score, and smoking status were independent risk factors for decreased VA diagnosed by VA < 80% prediction (Table 2).

3.3. Identification of Impairment in Pulmonary Diffusing Capacity. In our study, the BSI, FACED, E-FACED, and mMRC dyspnea scores were significantly higher in patients with impaired pulmonary diffusion dysfunction (diagnosed by DLCO < 80% prediction or DLCO/VA < 80% prediction) than in control individuals. The AUCs for the BSI, FACED, E-FACED, and mMRC scores for discriminating those pulmonary function abnormalities were shown (Figures 2(a) and 2(b)). Although the AUC for the BSI score appeared to be the largest, the difference between the BSI score and the others was not statistically significant (P = 0.181 for DLCO < 80% prediction and P = 0.105 for DLCO/VA < 80% prediction).

According to the Youden index, the optimal cutoff values for discriminating DLCO < 80% prediction were 11 for the BSI score (sensitivity, 75.2%; specificity, 76.6%; Youden index, 0.519), 3 for the FACED score (sensitivity, 76.5%; specificity, 72.3%; Youden index, 0.488), 5 for the E-FACED score (sensitivity, 76.5%; specificity, 74.5%; Youden index, 0.476). The optimal cutoff values for discriminating DLCO/VA < 80% prediction were 13 for the BSI score (sensitivity, 65.9%; specificity, 78.4%; Youden index, 0.443), 3 for the FACED score (sensitivity, 80.5%; specificity, 59.0%; Youden index, 0.395), 5 for the E-FACED score (sensitivity, 80.5%; specificity, 60.4%; Youden index, 0.409), and Grade 2 for the mMRC dyspnea score (sensitivity, 59.3%; specificity, 88.3%; Youden index, 0.476). The optimal cutoff values for discriminating DLCO/VA < 80% prediction were 11 for the BSI score (sensitivity, 75.2%; specificity, 76.6%; Youden index, 0.519), 3 for the FACED score (sensitivity, 76.5%; specificity, 72.3%; Youden index, 0.488), 5 for the E-FACED score (sensitivity, 76.5%; specificity, 74.5%; Youden index, 0.476). The optimal cutoff values for discriminating DLCO/VA < 80% prediction were 11 for the BSI score (sensitivity, 75.2%; specificity, 76.6%; Youden index, 0.519), 3 for the FACED score (sensitivity, 76.5%; specificity, 72.3%; Youden index, 0.488), 5 for the E-FACED score (sensitivity, 76.5%; specificity, 74.5%; Youden index, 0.476).

4. Discussion

In our study, several factors such as age, BMI, and Reiff score were associated with impaired pulmonary diffusing capacity among NCFB patients. COPD and ILD comorbidities, in particular, had independent effects on pulmonary diffusing impairment (DLCO < 80% prediction) in these patients. Further analysis showed that COPD played an independent role in decreasing DLCO/VA. Age and Reiff score played independent roles in decreasing VA. BMI and ILD might show combined effects on pulmonary diffusion through decreased DLCO/VA and VA, although they did not independently affect decreased DLCO/VA and VA when analyzed separately. Except for classical factors such as hemoglobin, disease duration, and frequency of exacerbation, would also affect pulmonary diffusion capacity diagnosed by DLCO/VA < 80% significantly. However, the BSI scoring system had the most significant area for discrimination of pulmonary diffusing impairment; it just showed a comparable performance compared with several other scoring methods, including a simple index of mMRC. The mMRC index, as a simple tool, would be helpful to evaluate the diffusing capacity of NCFB patients before the initiation.
|                          | Total (n) | Impaired diffusing capacity diagnosed by DLCO | P value | Impaired diffusing capacity diagnosed by DLCO/VA | P value | Decreased VA | P value |
|--------------------------|-----------|---------------------------------------------|---------|-----------------------------------------------|---------|--------------|---------|
|                          |           | ≥80% prediction                             | <80% prediction |                                  | ≥80% prediction | <80% prediction | ≥80% prediction | <80% prediction |         |
| **Number**               | 175       | 94                                          | 81      | 134                                          | 41      | 85           | 90      |         | <0.001 |
| Age (years)              |           | 175 (100%)                                  | 58.17 ± 12.53 | 66.84 ± 11.68                     | <0.001 | 60.66 ± 12.59 | 67.17 ± 12.61 | 0.004 | 58.62 ± 13.43 | 65.54 ± 11.39 | <0.001 |
| Sex, male                |           | 106 (60.5%)                                 | 53 (56.4%) | 53 (65.4%)                  | 0.22    | 77 (57.5%)   | 29 (70.7%)   | 0.128 | 41 (48.2%)   | 65 (72.2%)   | 0.001 |
| Hemoglobin (g/L)         |           | 175 (100%)                                  | 133.17 ± 17.36 | 125.99 ± 16.84                  | 0.006   | 131.29 ± 12.60 | 135.10 ± 12.61 | 0.047 | 129.98 ± 17.12 | 129.6910 ± 17.83 | 0.914 |
| Duration of disease (years) |           | 175 (100%)                                  | 0.84 (0.00, 5.00) | 6.00 (1.75, 10.00)            | <0.001 | 2.00 (0.60)  | 10.00 (5.00, 12.50) | <0.001 | 2.00 (0.70)  | 5.00 (0.10.00) | 0.006 |
| Modified Reiff score     |           | 175 (100%)                                  | 5.00 (3.00, 8.00) | 8.00 (5.00, 12.00)          | <0.001 | 6.00 (4.00, 9.25) | 8.00 (4.00, 12.00) | 0.037 | 5.00 (3.00, 8.00) | 8.00 (5.00, 11.00) | <0.001 |
| Frequency of hospitalization in the last 2 years |           | 175 (100%)                                  | 1.00 (1.00, 1.00) | 1.00 (1.00, 2.00)           | 0.02    | 1.00 (1.00, 1.00) | 2.00 (1.00, 2.00) | <0.001 | 1.00 (1.00, 1.00) | 2.00 (1.00, 2.00) | 0.108 |
| Frequency of exacerbation in the last 2 years |           | 175 (100%)                                  | 1.00 (1.00, 2.00) | 2.00 (1.00, 3.00)           | <0.001 | 1.00 (1.00, 2.00) | 3.00 (1.50, 3.00) | <0.001 | 1.00 (1.00, 2.00) | 2.00 (1.00, 3.00) | 0.083 |
| Body mass index (kg/m²)  |           | <18.5                                        | 34 (19.4%) | 9 (9.6%)                  | <0.001 | 19 (14.2%)   | 15 (36.6%)   | 0.003 | 11 (12.9%)   | 23 (25.6%)   | 0.031 |
|                          |           | 18.5–24                                      | 85 (48.6%) | 43 (45.7%)                  | <0.001 | 66 (49.3%)   | 19 (46.3%)   | 0.003 | 40 (47.1%)   | 45 (50.0%)   | 0.004 |
|                          |           | ≥24                                          | 56 (32.0%) | 42 (44.7%)                  | 0.003   | 49 (36.6%)   | 7 (17.1%)    | 0.011 | 34 (40.0%)   | 22 (24.4%)   | 0.005 |
| Smoking status           |           | Smoker or ex-smoker                          | 77 (44.0%) | 32 (34.0%)                  | 0.053   | 53 (39.6%)   | 24 (58.3%)   | 0.032 | 28 (32.9%)   | 49 (54.4%)   | 0.009 |
|                          |           | Non-smoker                                   | 98 (56.0%) | 62 (66.0%)                  | 0.053   | 81 (60.4%)   | 17 (41.5%)   | 0.032 | 57 (67.1%)   | 41 (45.6%)   | 0.004 |
| Pseudomonas aeruginosa colonization |          | Yes                                          | 12 (6.9%) | 3 (3.2%)                   | 0.04    | 8 (6.0%)     | 4 (9.8%)    | 0.627 | 4 (4.7%)     | 8 (8.9%)     | 0.274 |
|                          |           | No                                           | 163 (93.2%) | 91 (96.8%)                 | 0.04    | 126 (94.0%)  | 37 (90.2%)  | 81 (95.3%)  | 82 (91.1%)  |         |
| Lower airway pathogen detection |          | None                                         | 122 (69.7%) | 72 (76.6%)                 | 0.08    | 97 (72.4%)   | 25 (61.0%)  | 0.212 | 64 (75.3%)  | 58 (64.4%)  | 0.187 |
|                          |           | Pseudomonas aeruginosa                       | 22 (12.6%) | 8 (8.5%)                   | 0.14    | 14 (17.3%)   | 5 (12.2%)   | 0.727 | 7 (8.2%)    | 15 (16.7%)  | 0.011 |
|                          |           | Other pathogen                               | 31 (18.9%) | 14 (14.9%)                 | <0.001 | 20 (14.9%)   | 11 (26.8%)  | 0.124 | 14 (16.5%)  | 17 (18.9%)  | 0.001 |
| Chronic obstructive pulmonary disease |        | Yes                                          | 64 (36.6%) | 20 (21.3%)                 | <0.001 | 35 (26.1%)   | 29 (70.7%)  | <0.001 | 23 (27.1%)  | 41 (45.6%)  | 0.011 |
|                          |           | No                                           | 111 (63.4%) | 74 (78.7%)                 | 0.01    | 18 (13.4%)   | 2 (4.9%)    | 0.220 | 13 (15.3%)  | 7 (7.8%)   | 0.118 |
| Asthma                   |           | Yes                                          | 20 (11.4%) | 16 (17.0%)                 | 0.01    | 18 (13.4%)   | 2 (4.9%)    | 0.220 | 13 (15.3%)  | 7 (7.8%)   | 0.118 |
| Table 1: Continued. | Total (n) | Impaired diffusing capacity diagnosed by DLCO | $P$ value | Impaired diffusing capacity diagnosed by DLCO/VA | $P$ value | Decreased VA | $P$ value |
|---------------------|----------|---------------------------------------------|-----------|-----------------------------------------------|-----------|--------------|-----------|
|                     |          | $\geq 80\%$ prediction| $<80\%$ prediction |                  | $\geq 80\%$ prediction| $<80\%$ prediction |                  |
| No                  | 155 (88.6%) | 78 (83.0%) | 77 (95.1%) | 116 (86.6%) | 39 (95.1%) | 72 (84.7%) | 83 (92.2%) |
| Interstitial lung disease | Yes | 13 (7.4%) | 1 (7.7%) | 12 (92.3%) | 0.001 | 8 (6.0%) | 5 (12.2%) | 0.322 | 4 (4.7%) | 9 (10.0%) | 0.182 |
| No                  | 162 (92.6%) | 93 (57.4%) | 69 (42.6%) | 126 (94.0%) | 36 (87.8%) | 81 (95.3%) | 81 (90.0%) |
| Pulmonary arterial hypertension | Yes | 27 (15.4%) | 4 (4.3%) | 23 (28.4%) | 0.001 | 8 (6.0%) | 5 (12.2%) | $<0.001$ | 8 (9.4%) | 19 (21.1%) | 0.032 |
| No                  | 148 (84.6%) | 90 (95.7%) | 58 (71.6%) | 126 (94.0%) | 36 (87.8%) | 77 (90.6%) | 71 (78.9%) |
| Cardiovascular diseases | Yes | 56 (32.0%) | 23 (25.3%) | 33 (40.7%) | 0.02 | 38 (28.4%) | 18 (43.9%) | 0.062 | 25 (29.4%) | 31 (34.4%) | 0.476 |
| No                  | 119 (68.0%) | 71 (74.7%) | 48 (59.3%) | 96 (71.6%) | 23 (56.1%) | 60 (70.6%) | 59 (65.6%) |
| Diabetes mellitus | Yes | 20 (11.4%) | 12 (12.8%) | 8 (9.9%) | 0.55 | 16 (11.9%) | 4 (9.8%) | 0.917 | 11 (12.9%) | 9 (10.0%) | 0.541 |
| No                  | 155 (88.6%) | 82 (87.2%) | 73 (90.1%) | 118 (88.1%) | 37 (90.2%) | 74 (87.1%) | 81 (90.0%) |
| Gastroesophageal reflux disease | Yes | 21 (12.0%) | 12 (12.8%) | 9 (11.1%) | 0.74 | 17 (12.7%) | 4 (9.8%) | 0.818 | 7 (8.2%) | 14 (15.6%) | 0.136 |
| No                  | 154 (88.0%) | 82 (87.2%) | 72 (88.9%) | 117 (87.3%) | 37 (90.2%) | 78 (91.8%) | 76 (84.4%) |
| Other complications | Yes | 85 (48.6%) | 48 (51.1%) | 37 (45.7%) | 0.48 | 65 (48.5%) | 20 (48.8%) | 0.976 | 41 (48.2%) | 44 (48.9%) | 0.931 |
| No                  | 90 (51.4%) | 46 (48.9%) | 44 (54.3%) | 69 (51.5%) | 21 (51.2%) | 44 (51.8%) | 46 (51.1%) |
| Bronchi cystic dilation | Yes | 92 (52.6%) | 43 (45.7%) | 49 (60.5%) | 0.05 | 67 (50.0%) | 25 (61.0%) | 0.218 | 40 (47.1%) | 52 (57.8%) | 0.156 |
| No                  | 83 (47.4%) | 51 (54.3%) | 32 (39.5%) | 67 (50.0%) | 16 (39.0%) | 45 (52.9%) | 38 (42.2%) |
| Bronchi varicose dilation | Yes | 110 (62.9%) | 55 (58.5%) | 55 (67.9%) | 0.20 | 83 (61.9%) | 27 (65.9%) | 0.650 | 52 (61.2%) | 58 (64.4%) | 0.655 |
| No                  | 65 (37.1%) | 39 (41.5%) | 26 (32.1%) | 51 (38.1%) | 14 (34.1%) | 33 (38.8%) | 32 (35.6%) |
| Bronchi column dilation | Yes | 122 (69.7%) | 65 (69.1%) | 57 (70.4%) | 0.86 | 92 (68.7%) | 30 (73.2%) | 0.582 | 59 (69.4%) | 63 (70.0%) | 0.933 |
| No                  | 53 (30.3%) | 29 (30.9%) | 25 (29.7%) | 42 (31.3%) | 11 (26.8%) | 26 (30.6%) | 27 (30.0%) |
of systematic evaluation. Our findings may aid in identifying individuals at high risk of death and improve the management of these patients.

Bronchiectasis is a chronic respiratory disease, and most cases are idiopathic. The typical clinical symptoms include chronic cough, purulent sputum, dyspnea, and hemoptysis. The pathophysiology of the disease is very complex and still poorly understood. Bronchiectasis was previously thought to originate from small airways, gradually leading to the obstruction of more distal airways [11]. Thus, in most

![Figure 1: Differences in ventilation pulmonary dysfunction between NCFB patients with and without impaired pulmonary diffusing capacity diagnosed by DLCO <80% prediction (a), with and without impaired pulmonary diffusing capacity diagnosed by DLCO/VA <80% prediction (b), and with and without decreased alveolar volume by VA <80% prediction (c).](image-url)
Table 2: Multivariate analysis of risk factors associated with impaired pulmonary diffusing capacity diagnosed by DLCO <80% prediction (a) and DLCO/VA <80% prediction (b), and decreased alveolar volume diagnosed by VA <80% prediction (c) among non-CF bronchiectasis patients.

| Age (years)                  | (a) Multivariate analysis of impaired pulmonary diffusing capacity diagnosed by DLCO <80% prediction | B-value | SE value | Wald value | OR value | 95% CI       | P value |
|------------------------------|-----------------------------------------------------------------------------------------------------|---------|----------|------------|----------|--------------|---------|
|                              |                                                                                                     | 0.475   | 0.019    | 6.346      | 1.048    | 1.010–1.087  | 0.0     |
| Body mass index              |                                                                                                     |         |          |            |          |              |         |
| <18.5                        |                                                                                                     | 1.250   | 0.525    | 5.667      | 3.490    | 1.247–9.766  | 0.017   |
| ≥24                          |                                                                                                     | −0.855  | 0.461    | 3.437      | 0.425    | 0.172–1.050  | 0.064   |
| 18.5–24                      |                                                                                                     | 1.217   | 0.413    | 8.693      | 3.377    | 1.504–7.582  | 0.003   |
| Chronic obstructive pulmonary disease |                                                                                                     |         |          |            |          |              |         |
| Interstitial lung disease    |                                                                                                     | 2.908   | 1.114    | 6.501      | 6.051    | 1.094–3.168  | 0.001   |
| Modified Reiff score         |                                                                                                     | 0.202   | 0.057    | 12.577     | 1.224    | 1.094–3.168  | 0.001   |
| (b) Multivariate analysis of impaired pulmonary diffusing capacity diagnosed by DLCO/VA <80% prediction |                                                                                                     |         |          |            |          |              |         |
| Duration of disease (years)  |                                                                                                     | 0.061   | 0.020    | 9.866      | 1.063    | 1.023–1.105  | 0.002   |
| Frequency of exacerbation in the last 2 years |                                                                                                     | 0.200   | 0.018    | 3.440      | 1.221    | 0.989–1.508  | 0.064   |
| Hemoglobin (g/L)             |                                                                                                     | −0.033  | 0.013    | 6.077      | 0.968    | 0.943–0.993  | 0.014   |
| Chronic obstructive pulmonary disease |                                                                                                     | 2.037   | 0.449    | 20.547     | 7.669    | 5            | <0.001  |
| (c) Multivariate analysis of decreased alveolar volume diagnosed by VA <80% prediction |                                                                                                     |         |          |            |          |              |         |
| Age (years)                  |                                                                                                     | 0.037   | 0.019    | 6.124      | 1.038    | 1.008–1.069  | 0.013   |
| Modified Reiff score         |                                                                                                     | 0.238   | 0.051    | 21.674     | 1.269    | 1.148–1.408  | <0.001  |
| Smokers or ex-smokers        |                                                                                                     | 1.004   | 0.367    | 7.490      | 2.729    | 1.330–5.602  | 0.006   |

In our study, although univariate analysis revealed that *Pseudomonas aeruginosa* colonization is associated with impaired pulmonary diffusing capacity, the association was not confirmed in multivariate regression analysis. Similar findings were reported by King et al. [13] and Guan et al. [15]. However, it remains controversial whether *Pseudomonas aeruginosa* colonization directly impacts lung function. In China, a retrospective multicenter study showed that *Pseudomonas aeruginosa* colonization could easily lead to abnormalities in pulmonary ventilation and diffusion function, which may further result in unfavorable outcomes, such as dyspnea acute exacerbation severe anxiety and depression, and even mortality. Besides these, *Pseudomonas aeruginosa* colonization is also associated with a significant annual decline in FEV1 [20]. Therefore, it is easy to conclude that *Pseudomonas aeruginosa* colonization
could be used to indicate disease severity. Further study is required to investigate the association between *Pseudomonas aeruginosa* colonization and pulmonary diffusion function in the future.

BSI, FACED, and E-FACED are three scoring systems recommended to evaluate bronchiectasis severity. The three scoring systems all constitute the predicted FEV1% variable, which represents the degree of obstruction. In our study, the BSI scoring system appeared to have the largest AUC in predicting impaired pulmonary diffusing capacity among NCFB patients. However, the difference between BSI and other systems did not reach statistical significance. For comparing the clinical utility of those scoring systems, many validated cohorts were examined. The results demonstrated that the BSI score outperformed other systems for predicting the decline of activity tolerance and lung function, including the risk of acute exacerbation and hospitalization [20], but was comparable for predicting mortality [21, 22].

In addition, unlike multidimensional scoring systems, the mMRC scoring system is straightforward to use. The index was mainly designed for the clinical evaluation of activity tolerance. In our study, the predictive capacity of the mMRC scoring system was moderate for discriminating between patients with and without lung diffusing dysfunction. Although the AUC of mMRC appeared to be the smallest, the system showed high specificity (88.3% for DLCO <80% prediction and 76.1% for DLCO/VA <80%

**Figure 2**: ROC curve analysis of mMRC dyspnea index and different scoring systems for discriminating non-CF bronchiectasis patients with impaired pulmonary diffusing capacity diagnosed by DLCO <80% prediction (a) or DLCO/VA <80% prediction (b).
prediction). Therefore, the mMRC scoring system is a helpful screening tool for the initial evaluation of lung function, even in cost-constrained healthcare environments.

5. Conclusion
In NCFB patients, age, low BMI, High Reiff score, and comorbidity with COPD and ILD are independent risk factors for impaired pulmonary diffusing capacity diagnosed by DLCO <80% prediction. Besides hemoglobin, frequency of exacerbation and disease duration also significantly affect pulmonary diffusion (DLCO/VA <80% prediction). In addition, our study suggests that the BSI, FACED, and E-FACED scoring systems show desirable predictive ability for impaired pulmonary diffusing capacity in NCFB patients; and that mMRC, as a simple screening tool, is useful even in cost-constrained healthcare environments.

Abbreviations
NCFB: Noncystic fibrosis bronchiectasis
COPD: Chronic obstructive pulmonary disease
ILD: Interstitial lung disease
PAH: Pulmonary artery hypertension
BMI: Body mass index
BSI: Bronchiectasis Severity Index
mMRC: Modified Medical Research Council
CT: Computerized tomography
AIDS: Acquired immunodeficiency syndrome
DLCO: Carbon monoxide diffusing capacity
VA: Alveolar volume
DLCO/VA: Carbon monoxide diffusing capacity divided by alveolar volume
FEV1: Forced expiratory volume in 1 s
FVC: Forced vital capacity
TLC: Total lung volume
RV: Residual volume
SD: Standard deviation
ROC: Receiver-operating characteristic
AUC: Area under the curve.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval
The study protocol was approved by the Ethics Review Committee of Longyan First Affiliated Hospital, Fujian Medical University. Written informed consent was obtained from all patients included in the study.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
The first two authors contribute to the paper equally. Kaijun Zhang and Xin Zou together collected clinical data from patients. Kaijun Zhang wrote the original draft. Xin Zou revised and edited the paper and responded to the funding acquisition. Zhiyi Ma was responsible for the supervision and professional consultation. Xiaohong Liu performed lung function tests for the patients. Chencheng Qiu, Lingyan Xie, Zhaoqiang Lin, Saiyu Li, and Yongming Wu helped collect patients from the clinic.

Acknowledgments
The authors thank Medjaden Inc. for scientific editing of this manuscript. This work was supported by the Start-Up Funding for Scientific Research in Fujian Medical University (Grant number: 2017XQ1184) and Fujian Provincial Health Technology Project (Grant number: 2018-1-98).

References
[1] Pulmonology Portuguese Society Bronchiectasis Study Group, “Recommendations for aetiological diagnosis of bronchiectasis,” Revista Portuguesa de Pneumologia, vol. 22, no. 4, pp. 222–235, 2016.
[2] J. K. Quint, E. R. C. Millett, M. Joshi et al., “Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study,” European Respiratory Journal, vol. 47, no. 1, pp. 186–193, 2016.
[3] R. Diel, S. Ewig, S. Blaas et al., “Incidence of patients with non-cystic fibrosis bronchiectasis in Germany—a healthcare insurance claims data analysis,” Respiratory Medicine, vol. 151, pp. 121–127, 2019.
[4] A. E. Seitz, K. N. Olivier, J. Adjemian, S. M. Holland, and D. R. Prevots, “Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007,” Chest, vol. 142, no. 2, pp. 432–439, 2012.
[5] H. J. Kwak, J.-Y. Moon, Y. W. Choi et al., “High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program,” Tohoku Journal of Experimental Medicine, vol. 222, no. 4, pp. 237–242, 2010.
[6] Y. M. Zhou, C. Wang, W. Z. Yao et al., “The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China,” Zhonghua Nei Ke Za Zhi, vol. 52, no. 5, pp. 379–382, 2013.
[7] J. D. Chalmers, P. Goeminne, S. Aliberti et al., “The bronchiectasis severity index. an international derivation and validation study,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 5, pp. 576–585, 2014.
[8] M. A. Martinez-Garcia, J. de Gracia, M. Vendrell Relat et al., “Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score,” European Respiratory Journal, vol. 43, no. 5, pp. 1357–1367, 2014.
[9] M. A. Martinez-Garcia, R. A. Athanazio, R. M. Girón et al., “Predicting high risk of exacerbations in bronchiectasis: the E-FACED score,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 12, pp. 275–284, 2017.
[10] M. R. Loebinger, A. U. Wells, D. M. Hansell et al., “Mortality in bronchiectasis: a long-term study assessing the factors influencing survival,” European Respiratory Journal, vol. 34, no. 4, pp. 843–849, 2009.
[11] F. Whitwell, “A study of the pathology and pathogenesis of bronchiectasis,” *Thorax*, vol. 7, no. 3, pp. 213–239, 1952.
[12] D. Radovanovic, P. Santus, F. Blasi et al., “A comprehensive approach to lung function in bronchiectasis,” *Respiratory Medicine*, vol. 145, pp. 120–129, 2018.
[13] P. T. King, S. R. Holdsworth, N. J. Freezer et al., “Lung diffusing capacity in adult bronchiectasis: a longitudinal study,” *Respiratory Care*, vol. 55, no. 12, pp. 1686–1692, 2010.
[14] D. A. Lynch, J. Newell, V. Hale et al., “Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis,” *American Journal of Roentgenology*, vol. 173, no. 1, pp. 53–58, 1999.
[15] W.-J. Guan, Y.-H. Gao, G. Xu et al., “Characterization of lung function impairment in adults with bronchiectasis,” *PLoS One*, vol. 9, no. 11, Article ID e113373, 2014.
[16] C. T. Tan, Z. Y. He, X. Y. Xin, and C. S. Guan, “Correlation between pulmonary function tests and high resolution computed tomography in bronchiectasis,” *International Journal of Respiration*, vol. 28, no. 23, pp. 1430–1432, 2008.
[17] M. Maglione, A. Bush, K. G. Nielsen et al., “Multicenter analysis of body mass index, lung function, and sputum microbiology in primary ciliary dyskinesia,” *Pediatric Pulmonology*, vol. 49, no. 12, pp. 1243–1250, 2014.
[18] L. King, H. White, I. Clifton, G. Spoletini, T. Ispoglou, and D. G. Peckham, “Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB)—a cross sectional study,” *Clinical Nutrition*, vol. 40, no. 9, pp. 5162–5168, 2021.
[19] E. Polverino, K. Dimakou, J. Hurst et al., “The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions,” *European Respiratory Journal*, vol. 52, no. 3, Article ID 1800328, 2018.
[20] M. Buscot, H. Pottier, C.-H. Marquette, and S. Leroy, “Phenotyping adults with non-cystic fibrosis bronchiectasis: a 10-year cohort study in a French regional university hospital center,” *Respiration*, vol. 92, no. 1, pp. 1–8, 2016.
[21] M. J. McDonnell, S. Aliberti, P. C. Goeminne et al., “Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts,” *Thorax*, vol. 71, no. 12, pp. 1110–1118, 2016.
[22] W.-L. Sheng, Y. X. Zhang, Y. Zhao, F. X. Yin, and Y. N. Liu, “Comparison between bronchiectasis severity index and FACED score for the prognostic assessment of bronchiectasis,” *International Journal of Respiration*, vol. 12, pp. 926–929, 2016.